$ELV

PERU RAMIRO G purchased $366K of ELV

PERU RAMIRO G purchased 1,000 shares of Elevance Health, Inc. (ELV) at $366.05 ($0.37M total) on 2026-07-17.

Original reporting
SEC EDGAR · PERU RAMIRO G
Published Jul 17, 2026, 7:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 7:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ELV
Bullish
medium confidence
Mentioned
$ELV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVBullishLow
01

Why it matters

The newest concrete fact is the director’s open-market purchase of 1,000 shares at a stated price on 2026-07-17.

02

Market read

Traders may monitor for follow-on insider activity, but this single Form 4 purchase is unlikely to move the stock materially by itself.

03

What to watch

The article does not state whether the purchase was part of a broader pattern, nor does it provide context on prior holdings changes beyond the post-transaction share count.

Relevance 5/10Novelty 5/10Timing: filed same day, 2026-07-17 (after-hours/late session disclosure)

Background

The article is an SEC Form 4 insider transaction disclosure for Elevance Health, Inc.

Company-level read

Ticker impact

$ELVBullishMedium confidence
Context

Elevance Health director PERU RAMIRO G bought 1,000 shares on 2026-07-17 at $366.05, totaling $366,050, per Form 4.

Expected impact

Likely limited near-term price impact; any effect is sentiment-driven and typically fades.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction size and lack of 10b5-1 pre-arrangement details reduce signal strength for trading decisions.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider open-market buys can be driven by diversification, liquidity needs, or non-informational motives, so the signal may be weak.

Key entities

  • Elevance Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • PERU RAMIRO G

    Director who purchased 1,000 shares on 2026-07-17.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.

$ELVMedAI 8/10

Elevance holds loss ratio guidance above 90% as fall renewals near

Elevance Health reaffirmed its 2026 benefit expense ratio guidance at 90.2% (+/- 0.5%), indicating stable medical utilization and specialty pharmacy costs. The company expects to meet its adjusted earnings guidance of at least $27 per diluted share. Q2 2026 results showed an 89.7% ratio, up 0.8% YoY, driven by government business costs. Elevance, the second-largest US health insurer, processes pharmacy claims through Carelon. Steady ratio signals heavy claims payouts, impacting fall renewals.

$ELVHighAI 8/10

Elevance Health reaffirms 2026 earnings and benefit expense guidance

Elevance Health (ELV) reaffirmed its 2026 earnings guidance of at least $20.10 per diluted share, including $6.90 in net unfavorable items, and adjusted earnings of at least $27.00 per share. The company also confirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. This follows strong Q2 2026 results, with adjusted earnings of $7.45 per share and revenue of $49.8 billion, but shares faced pressure due to Medicaid concerns. Analysts have mixed price targets and ra